Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment

Detalhes bibliográficos
Autor(a) principal: Macedo,Erick Marcet Santiago de
Data de Publicação: 2012
Outros Autores: Carneiro,Rachel Camargo, Carricondo,Pedro Carlos, Matayoshi,Suzana
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802012000300007
Resumo: PURPOSE: The objective of this study was to compare the estimated cost of clinical and surgical treatment for basl cell carcinoma of the eyelid. METHODS: This was a pilot study of 12 patients with basal cell carcinoma receiving treatment with 5% imiquimod cream at the ocular plastic surgery center, medical school University of São Paulo (HC-FMUSP, Brazil). The cost of clinical treatment was estimated based on the time of treatment and amount of medication consumed by patients in the home setting. The cost of surgical treatment was estimated by ophthalmologists with experience in reconstructive plastic surgery based on analysis of images of the same patients. Surgeons responded to a questionnaire with four questions about surgical technique, surgical materials required, estimated duration of surgery and type of anesthesia. RESULTS: Immunotherapy lasted from 8 to 12 weeks.All patients reported each coldstored sachet with 5% imiquimod cream lasted 3 days.According to the institution, a box with 12 sachets costs BRL 480.00. Patients required 1.58-3.11 boxes for complete treatment, corresponding to a total cost of BRL 758.401,492.80. Based on image analysis, surgeons evaluated surgery would require 1-3 hours. The estimated cost of surgery room and staff was BRL 263.00, to which the cost of supplies was added. Thus, the total cost of surgical treatment was BRL 272.61-864.82. On the average, immunotherapy was 57,64% more costly than surgical treatment. CONCLUSIONS: Malignant eyelid tumors are a common finding in clinical ophthalmology. Surgery is still the treatment of choice at our institution, but immunotherapy with 5% imiquimod cream may be indicated for patients with multiple lesions or high surgical risk and for patients declining surgery for reasons of fear or esthetic concerns.The ability to estimate costs related to the treatment of malignant eyelid tumors is an important aid in the financial planning of health care institutions. Further studies should evaluate the possibility of institutions equating the cost of immunotherapy and surgical treatment by acquiring similar but less expensive medications.
id SBO-1_bce80135896b8e73c48805936631cd9c
oai_identifier_str oai:scielo:S0034-72802012000300007
network_acronym_str SBO-1
network_name_str Revista Brasileira de Oftalmologia (Online)
repository_id_str
spelling Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatmentCarcinoma, basal cell carcinoma/surgeryCarcinoma, basal cell/economyCarcinoma, basal cell carcinoma/drug therapyEyelid neoplasmsAntineoplastic agents/therapeutic useBiopsyHealth care costsPURPOSE: The objective of this study was to compare the estimated cost of clinical and surgical treatment for basl cell carcinoma of the eyelid. METHODS: This was a pilot study of 12 patients with basal cell carcinoma receiving treatment with 5% imiquimod cream at the ocular plastic surgery center, medical school University of São Paulo (HC-FMUSP, Brazil). The cost of clinical treatment was estimated based on the time of treatment and amount of medication consumed by patients in the home setting. The cost of surgical treatment was estimated by ophthalmologists with experience in reconstructive plastic surgery based on analysis of images of the same patients. Surgeons responded to a questionnaire with four questions about surgical technique, surgical materials required, estimated duration of surgery and type of anesthesia. RESULTS: Immunotherapy lasted from 8 to 12 weeks.All patients reported each coldstored sachet with 5% imiquimod cream lasted 3 days.According to the institution, a box with 12 sachets costs BRL 480.00. Patients required 1.58-3.11 boxes for complete treatment, corresponding to a total cost of BRL 758.401,492.80. Based on image analysis, surgeons evaluated surgery would require 1-3 hours. The estimated cost of surgery room and staff was BRL 263.00, to which the cost of supplies was added. Thus, the total cost of surgical treatment was BRL 272.61-864.82. On the average, immunotherapy was 57,64% more costly than surgical treatment. CONCLUSIONS: Malignant eyelid tumors are a common finding in clinical ophthalmology. Surgery is still the treatment of choice at our institution, but immunotherapy with 5% imiquimod cream may be indicated for patients with multiple lesions or high surgical risk and for patients declining surgery for reasons of fear or esthetic concerns.The ability to estimate costs related to the treatment of malignant eyelid tumors is an important aid in the financial planning of health care institutions. Further studies should evaluate the possibility of institutions equating the cost of immunotherapy and surgical treatment by acquiring similar but less expensive medications.Sociedade Brasileira de Oftalmologia2012-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802012000300007Revista Brasileira de Oftalmologia v.71 n.3 2012reponame:Revista Brasileira de Oftalmologia (Online)instname:Sociedade Brasileira de Oftalmologia (SBO)instacron:SBO10.1590/S0034-72802012000300007info:eu-repo/semantics/openAccessMacedo,Erick Marcet Santiago deCarneiro,Rachel CamargoCarricondo,Pedro CarlosMatayoshi,Suzanaeng2012-07-31T00:00:00Zoai:scielo:S0034-72802012000300007Revistahttps://rbo.emnuvens.com.br/rbo/indexhttps://old.scielo.br/oai/scielo-oai.phpsob@sboportal.org.br||rbo@sboportal.org.br1982-85510034-7280opendoar:2012-07-31T00:00Revista Brasileira de Oftalmologia (Online) - Sociedade Brasileira de Oftalmologia (SBO)false
dc.title.none.fl_str_mv Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment
title Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment
spellingShingle Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment
Macedo,Erick Marcet Santiago de
Carcinoma, basal cell carcinoma/surgery
Carcinoma, basal cell/economy
Carcinoma, basal cell carcinoma/drug therapy
Eyelid neoplasms
Antineoplastic agents/therapeutic use
Biopsy
Health care costs
title_short Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment
title_full Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment
title_fullStr Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment
title_full_unstemmed Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment
title_sort Periocular basal cell carcinoma: cost of topical immunotherapy versus estimated cost of surgical treatment
author Macedo,Erick Marcet Santiago de
author_facet Macedo,Erick Marcet Santiago de
Carneiro,Rachel Camargo
Carricondo,Pedro Carlos
Matayoshi,Suzana
author_role author
author2 Carneiro,Rachel Camargo
Carricondo,Pedro Carlos
Matayoshi,Suzana
author2_role author
author
author
dc.contributor.author.fl_str_mv Macedo,Erick Marcet Santiago de
Carneiro,Rachel Camargo
Carricondo,Pedro Carlos
Matayoshi,Suzana
dc.subject.por.fl_str_mv Carcinoma, basal cell carcinoma/surgery
Carcinoma, basal cell/economy
Carcinoma, basal cell carcinoma/drug therapy
Eyelid neoplasms
Antineoplastic agents/therapeutic use
Biopsy
Health care costs
topic Carcinoma, basal cell carcinoma/surgery
Carcinoma, basal cell/economy
Carcinoma, basal cell carcinoma/drug therapy
Eyelid neoplasms
Antineoplastic agents/therapeutic use
Biopsy
Health care costs
description PURPOSE: The objective of this study was to compare the estimated cost of clinical and surgical treatment for basl cell carcinoma of the eyelid. METHODS: This was a pilot study of 12 patients with basal cell carcinoma receiving treatment with 5% imiquimod cream at the ocular plastic surgery center, medical school University of São Paulo (HC-FMUSP, Brazil). The cost of clinical treatment was estimated based on the time of treatment and amount of medication consumed by patients in the home setting. The cost of surgical treatment was estimated by ophthalmologists with experience in reconstructive plastic surgery based on analysis of images of the same patients. Surgeons responded to a questionnaire with four questions about surgical technique, surgical materials required, estimated duration of surgery and type of anesthesia. RESULTS: Immunotherapy lasted from 8 to 12 weeks.All patients reported each coldstored sachet with 5% imiquimod cream lasted 3 days.According to the institution, a box with 12 sachets costs BRL 480.00. Patients required 1.58-3.11 boxes for complete treatment, corresponding to a total cost of BRL 758.401,492.80. Based on image analysis, surgeons evaluated surgery would require 1-3 hours. The estimated cost of surgery room and staff was BRL 263.00, to which the cost of supplies was added. Thus, the total cost of surgical treatment was BRL 272.61-864.82. On the average, immunotherapy was 57,64% more costly than surgical treatment. CONCLUSIONS: Malignant eyelid tumors are a common finding in clinical ophthalmology. Surgery is still the treatment of choice at our institution, but immunotherapy with 5% imiquimod cream may be indicated for patients with multiple lesions or high surgical risk and for patients declining surgery for reasons of fear or esthetic concerns.The ability to estimate costs related to the treatment of malignant eyelid tumors is an important aid in the financial planning of health care institutions. Further studies should evaluate the possibility of institutions equating the cost of immunotherapy and surgical treatment by acquiring similar but less expensive medications.
publishDate 2012
dc.date.none.fl_str_mv 2012-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802012000300007
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802012000300007
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0034-72802012000300007
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Oftalmologia
publisher.none.fl_str_mv Sociedade Brasileira de Oftalmologia
dc.source.none.fl_str_mv Revista Brasileira de Oftalmologia v.71 n.3 2012
reponame:Revista Brasileira de Oftalmologia (Online)
instname:Sociedade Brasileira de Oftalmologia (SBO)
instacron:SBO
instname_str Sociedade Brasileira de Oftalmologia (SBO)
instacron_str SBO
institution SBO
reponame_str Revista Brasileira de Oftalmologia (Online)
collection Revista Brasileira de Oftalmologia (Online)
repository.name.fl_str_mv Revista Brasileira de Oftalmologia (Online) - Sociedade Brasileira de Oftalmologia (SBO)
repository.mail.fl_str_mv sob@sboportal.org.br||rbo@sboportal.org.br
_version_ 1752122336355549184